The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30589627.
- Also identified by DOI 10.18553/jmcp.2019.25.1.010 and PMC identifier 10398025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.
Medical subject headings
- Amyloid Neuropathies, Familial
- Oligodeoxyribonucleotides, Antisense
- Oligonucleotides
- Prealbumin
- RNA, Small Interfering